What does this research mean for the field?

Tirzepatide use in adults with type 1 diabetes and overweight or obesity is associated with substantial weight loss, improved HbA1c, and reduced total daily insulin dose without increasing hypoglycemia. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aimed to evaluate the effects of tirzepatide on metabolic outcomes in adults with type 1 diabetes and obesity.

June 7, 2026Diabetes

1729-P: Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital

View Full Paper

Ask AI

Bookmark

This research aimed to evaluate the effects of tirzepatide on metabolic outcomes in adults with type 1 diabetes and obesity.
Conducted a retrospective cohort study at Royal North Shore Hospital from 2020 to 2025.
Included adults aged ≥18 years with type 1 diabetes, BMI ≥27 kg/m², and used a continuous glucose monitor, with follow-up after ≥3 months.
Matched tirzepatide users with controls in a 1:1 ratio for comparison.
Tirzepatide users experienced a weight loss of -9.75 kg versus +1.72 kg in controls (p<0.0001).
HbA1c decreased more in the tirzepatide group (-0.58%) compared to controls (-0.01%; p<0.05).
Total daily insulin dose reduced significantly by -24.7 U for tirzepatide users vs. an increase of +9.13 U in controls (p<0.05).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective cohort study demonstrates tirzepatide enhances metabolic outcomes in adults with type 1 diabetes and obesity, suggesting potential benefits for treatment.

Cite This Study

Purcell et al. (2026) studied this question.

synapsesocial.com/papers/6a250cbc7def13d035e1cf2a https://doi.org/10.2337/db26-1729-p

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study demonstrates tirzepatide enhances metabolic outcomes in adults with type 1 diabetes and obesity, suggesting potential benefits for treatment.

1729-P: Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital

Key Points

Discussion

Implication

Cite This Study

1729-P: Tirzepatide Enhances Metabolic Outcomes in People with Type 1 Diabetes and Overweight/Obesity: A Retrospective Cohort Study at Sydney's Royal North Shore Hospital

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider